CD226 Antikörper (AA 19-254)
-
- Target Alle CD226 Antikörper anzeigen
- CD226
-
Bindungsspezifität
- AA 19-254
-
Reaktivität
- Human
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser CD226 Antikörper ist unkonjugiert
-
Applikation
- ELISA
- Verwendungszweck
- CD226 Antibody
- Aufreinigung
- Purified antibody
- Immunogen
- Purified recombinant fragment of human CD226 (AA: 19-254) expressed in E. Coli.
- Klon
- 8D11D5
- Isotyp
- IgG1
- Top Product
- Discover our top product CD226 Primärantikörper
-
-
- Applikationshinweise
- ELISA: 1/10000
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
- Purified antibody in PBS with 0.05 % sodium azide.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
-
- Target
- CD226
- Andere Bezeichnung
- CD226 (CD226 Produkte)
- Synonyme
- CD226 antikoerper, cd226 antikoerper, zgc:158817 antikoerper, BC051526 antikoerper, DNAM-1 antikoerper, DNAM1 antikoerper, Pta1 antikoerper, TLiSA1 antikoerper, PTA1 antikoerper, CD226 molecule antikoerper, CD226 antigen antikoerper, CD226 antikoerper, cd226 antikoerper, Cd226 antikoerper
- Hintergrund
-
Description: This gene encodes a glycoprotein expressed on the surface of NK cells, platelets, monocytes and a subset of T cells. It is a member of the Ig-superfamily containing 2 Ig-like domains of the V-set. The protein mediates cellular adhesion of platelets and megakaryocytic cells to vascular endothelial cells. The protein also plays a role in megakaryocytic cell maturation. Alternative splicing results in multiple transcript variants.
Aliases: PTA1, DNAM1, DNAM-1, TLiSA1
- Molekulargewicht
- 38.6kDa
- Gen-ID
- 10666
- HGNC
- 3673
- UniProt
- Q15762
- Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
-